NCT02125461
Who may be able to join
Who might be able to join this trial:
- You must be at least 18 years old
- You must have been diagnosed with a specific type of lung cancer called non-small cell lung cancer (NSCLC) that is at an advanced stage (Stage III) and cannot be removed by surgery
- You must have already received at least 2 cycles of a chemotherapy treatment containing platinum, given at the same time as radiation therapy
- You must be in generally good health and able to carry out daily activities with little or no difficulty (confirm with trial site)
- Your doctor must estimate that you are expected to live for more than 12 weeks
Who may not be able to join:
- You have previously been treated with certain types of immunotherapy drugs known as anti-PD-1 or anti-PD-L1 antibodies
- You have, or have had in the past, a condition where your immune system attacks your own body, or a condition that weakens your immune system
- You have serious or uncontrolled health conditions, including active bleeding problems, or active infections such as Hepatitis B, Hepatitis C, or HIV
- You have uncontrolled conditions such as heart failure with symptoms, very high blood pressure that cannot be managed, or chest pain caused by reduced blood flow to the heart
- You are still experiencing side effects from your previous chemotherapy and radiation treatment that are more than mild in severity (confirm with trial site)
- You have, or have had in the past, an inflammatory bowel disease such as Crohn's disease or ulcerative colitis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Where this trial is recruiting
13 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1); Overall Survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.